AR088379A1 - Formulaciones de etanercept estabilizadas con iones metalicos - Google Patents

Formulaciones de etanercept estabilizadas con iones metalicos

Info

Publication number
AR088379A1
AR088379A1 ARP120103885A ARP120103885A AR088379A1 AR 088379 A1 AR088379 A1 AR 088379A1 AR P120103885 A ARP120103885 A AR P120103885A AR P120103885 A ARP120103885 A AR P120103885A AR 088379 A1 AR088379 A1 AR 088379A1
Authority
AR
Argentina
Prior art keywords
formulations
metal ions
etanercept stabilized
etanercept
stabilized
Prior art date
Application number
ARP120103885A
Other languages
English (en)
Original Assignee
Coherus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coherus Biosciences Inc filed Critical Coherus Biosciences Inc
Publication of AR088379A1 publication Critical patent/AR088379A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)

Abstract

Composiciones farmacéuticas acuosas estabilizadas para el almacenamiento a largo plazo del etanercept.
ARP120103885A 2011-10-18 2012-10-18 Formulaciones de etanercept estabilizadas con iones metalicos AR088379A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161548518P 2011-10-18 2011-10-18
US201261669480P 2012-07-09 2012-07-09

Publications (1)

Publication Number Publication Date
AR088379A1 true AR088379A1 (es) 2014-05-28

Family

ID=48136153

Family Applications (6)

Application Number Title Priority Date Filing Date
ARP120103888A AR088382A1 (es) 2011-10-18 2012-10-18 Formulaciones de etanercept estabilizadas con xilitol
ARP120103887A AR088381A1 (es) 2011-10-18 2012-10-18 Formulaciones de etanercept estabilizadas con meglumina
ARP120103884A AR088460A1 (es) 2011-10-18 2012-10-18 Formulaciones de etanercept estabilizadas con aminoacidos
ARP120103889A AR088383A1 (es) 2011-10-18 2012-10-18 Formulaciones de etanercept estabilizadas con combinaciones de azucares y polioles
ARP120103886A AR088380A1 (es) 2011-10-18 2012-10-18 Formulaciones de etanercept estabilizadas con cloruro de sodio
ARP120103885A AR088379A1 (es) 2011-10-18 2012-10-18 Formulaciones de etanercept estabilizadas con iones metalicos

Family Applications Before (5)

Application Number Title Priority Date Filing Date
ARP120103888A AR088382A1 (es) 2011-10-18 2012-10-18 Formulaciones de etanercept estabilizadas con xilitol
ARP120103887A AR088381A1 (es) 2011-10-18 2012-10-18 Formulaciones de etanercept estabilizadas con meglumina
ARP120103884A AR088460A1 (es) 2011-10-18 2012-10-18 Formulaciones de etanercept estabilizadas con aminoacidos
ARP120103889A AR088383A1 (es) 2011-10-18 2012-10-18 Formulaciones de etanercept estabilizadas con combinaciones de azucares y polioles
ARP120103886A AR088380A1 (es) 2011-10-18 2012-10-18 Formulaciones de etanercept estabilizadas con cloruro de sodio

Country Status (27)

Country Link
US (21) US9801942B2 (es)
EP (6) EP2768525B1 (es)
JP (6) JP6104922B2 (es)
KR (7) KR20140091707A (es)
CN (6) CN103998060B (es)
AR (6) AR088382A1 (es)
AU (6) AU2012326168B2 (es)
BR (6) BR112014009022A2 (es)
CA (6) CA2851639C (es)
CY (1) CY1121843T1 (es)
DK (1) DK2768525T3 (es)
EA (6) EA027325B1 (es)
ES (1) ES2734070T3 (es)
HK (6) HK1200721A1 (es)
HR (1) HRP20191215T1 (es)
HU (1) HUE045624T2 (es)
IL (6) IL231824A0 (es)
IN (3) IN2014CN02592A (es)
LT (1) LT2768525T (es)
MX (7) MX2014004728A (es)
PL (1) PL2768525T3 (es)
PT (1) PT2768525T (es)
RS (1) RS59179B1 (es)
SG (6) SG11201401562RA (es)
SI (1) SI2768525T1 (es)
TW (6) TW201325606A (es)
WO (6) WO2013059412A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc PREPARATIONS OF SPONTANEOUS TAMPING PROTEINS
SG11201401562RA (en) * 2011-10-18 2014-09-26 Coherus Biosciences Inc Etanercept formulations stabilized with sodium chloride
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
CN104661651A (zh) * 2012-07-09 2015-05-27 科荣生生物科学公司 表现出不溶性微粒显著减少的依那西普制剂
ES2657377T3 (es) * 2012-09-11 2018-03-05 Coherus Biosciences, Inc. Etanercept plegado correctamente con alta pureza y excelente rendimiento
CA2911068A1 (en) * 2013-05-02 2014-11-06 Mabxience, S.A. Alternative formulations for tnfr: fc fusion polypeptides
WO2015056613A1 (ja) * 2013-10-15 2015-04-23 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 安定化されたポリペプチド水性製剤
CN113350278B (zh) * 2013-10-24 2023-03-24 阿斯利康(瑞典)有限公司 稳定的水性抗体配制品
CA2930227C (en) * 2013-11-29 2021-09-28 Ares Trading S.A. A liquid formulation of a fusion protein comprising tnfr and fc region
IS3008B (is) * 2014-05-14 2018-12-15 Calor ehf Stöðgandi lausnir fyrir prótín og peptíð
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US20180200325A1 (en) * 2014-11-18 2018-07-19 Shionogi & Co., Ltd. Stabilized peptide composition
EP3236990B1 (en) * 2014-12-22 2020-09-02 Ares Trading S.A. Liquid pharmaceutical composition
WO2016103034A1 (en) * 2014-12-23 2016-06-30 Drug Discovery Laboratory As Protein compositions and use thereof
MX2017008633A (es) 2014-12-31 2018-04-26 Lg Chemical Ltd Procedimiento para preparar una proteina de fusion tnfr-fc que contiene un contenido objetivo de impurezas.
CN104694355B (zh) * 2015-03-20 2016-09-28 吉林大学 葛根护肝保健酒及其制备方法
MX2015010517A (es) * 2015-08-13 2017-02-13 Landsteiner Scient S A De C V Composicion de estabilidad mejorada de etanercept.
JP5938762B1 (ja) * 2015-09-01 2016-06-22 日揮株式会社 マイクロカプセル製剤及びその製造方法
CN105748414A (zh) * 2016-03-02 2016-07-13 张光泉 抗感染米卡芬净冻干组合物及其制备方法
JPWO2017179683A1 (ja) * 2016-04-15 2019-02-21 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 ミカファンギンの安定化された医薬組成物
JP6884858B2 (ja) 2016-10-21 2021-06-09 アムジエン・インコーポレーテツド 医薬製剤及びその製造方法
KR20180046888A (ko) 2016-10-28 2018-05-09 (주)셀트리온 안정한 약제학적 제제
MX2017013995A (es) * 2017-10-31 2019-05-01 Probiomed S A De C V Formulacion farmaceutica estable de una proteina de fusion.
CN111110842B (zh) * 2017-11-30 2020-12-11 百奥泰生物制药股份有限公司 一种治疗il-6相关疾病的人源化抗体的液体制剂
AU2018388301B2 (en) * 2017-12-22 2022-02-17 Samsung Bioepis Co., Ltd. Liquid composition comprising VEGF antagonist
US11253569B2 (en) 2018-05-03 2022-02-22 Seattle Children's Hospital Methods of treating Kawasaki Disease
CN111228225B (zh) * 2018-11-28 2022-08-26 鲁南制药集团股份有限公司 一种重组人肿瘤坏死因子受体-Fc融合蛋白冻干制剂
GB201911461D0 (en) * 2019-08-09 2019-09-25 Arecor Ltd Novel composition
EP4065166A4 (en) * 2019-11-26 2023-12-20 Comera Life Sciences, Inc. EXCIPIENT COMPOUNDS FOR BIOPOLYMER FORMULATIONS
CN116867481A (zh) 2021-02-17 2023-10-10 艾瑞克有限公司 包含Fc结构域的工程化蛋白质构建体的水性组合物
CN114788809B (zh) * 2022-01-25 2023-04-14 江苏广承药业有限公司 一种氯雷他定液体制剂

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
WO1994006476A1 (en) 1992-09-15 1994-03-31 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5656730A (en) 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
US6677326B2 (en) * 1999-03-15 2004-01-13 Arakis, Ltd. Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
WO2000062790A2 (en) 1999-04-19 2000-10-26 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
MXPA02007683A (es) 2000-02-10 2002-12-13 American Home Prod Metodo para tratar o inhibir la lesion celular o muerte celular.
ES2644275T3 (es) 2000-08-11 2017-11-28 Chugai Seiyaku Kabushiki Kaisha Preparaciones estabilizadas que contienen anticuerpos
US6936437B2 (en) * 2001-02-23 2005-08-30 Lucia Irene Gonzalez-Villasenor Methods and compositions for production of recombinant peptides
ES2311094T3 (es) * 2002-02-27 2009-02-01 Immunex Corporation Composicion estabilizada de tnfr-fc que comprende arginina.
JP4980048B2 (ja) * 2003-02-28 2012-07-18 アレス トレーディング ソシエテ アノニム 腫瘍壊死因子結合タンパク質の液体製剤
EP1607103A1 (en) 2003-03-20 2005-12-21 Eisai Co., Ltd. Concomitant drug as therapeutic agent for inflammatory bowel disease
BRPI0413197A (pt) 2003-08-01 2006-10-03 Amgen Inc cristal de eta wercept; método para fabricar um cristal de etanercept; composição; uso de um cristal de etanercept
NZ546347A (en) 2003-10-14 2009-11-27 Intermune Inc Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication
JP5554466B2 (ja) 2004-03-01 2014-07-23 味の素株式会社 抗ヒトＴＮＦ−α抗体活性低下抑制剤
EP2308958A3 (en) 2004-03-05 2011-08-10 DSM IP Assets B.V. Process for cell culturing by continuous perfusion and alternating tangential flow
US20070196364A1 (en) * 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
JP5339901B2 (ja) 2005-05-10 2013-11-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド 炎症傷害の処置および評価
KR101367544B1 (ko) * 2005-06-10 2014-02-26 추가이 세이야쿠 가부시키가이샤 메글루민을 함유하는 단백질 제제의 안정화제, 및 그의이용
EP1909831A4 (en) * 2005-06-14 2013-02-20 Amgen Inc PREPARATIONS OF SPONTANEOUS TAMPING PROTEINS
WO2007076354A2 (en) * 2005-12-20 2007-07-05 Bristol-Myers Squibb Company Stable protein formulations
CN101378782A (zh) * 2005-12-21 2009-03-04 惠氏公司 粘度降低的蛋白质制剂及其用途
JP2009525986A (ja) 2006-02-03 2009-07-16 メディミューン，エルエルシー タンパク質製剤
JP5374359B2 (ja) * 2006-03-17 2013-12-25 バイオジェン・アイデック・エムエイ・インコーポレイテッド 安定化されたポリペプチド化合物
EP1996076A2 (en) 2006-03-21 2008-12-03 Eugen Oetringer Devices for and methods of analyzing a physiological condition of a physiological subject based on a workload related property
US20080003220A1 (en) 2006-04-21 2008-01-03 Amgen, Inc. Buffering agents for biopharmaceutical formulations
CN103540575A (zh) * 2006-08-01 2014-01-29 奇尼塔二有限责任公司 医药制造方法
EP2081553B1 (en) * 2006-10-06 2020-08-12 Amgen Inc. Stable antibody formulations
EP2094247B1 (en) * 2006-10-20 2022-06-29 Amgen Inc. Stable polypeptide formulations
EP2395077A1 (en) 2006-11-03 2011-12-14 Wyeth LLC Glycolysis-inhibiting substances in cell culture
CA2672902C (en) * 2006-12-21 2012-11-27 Amgen Inc. Formulations
AU2008223133A1 (en) 2007-03-02 2008-09-12 Wyeth Use of copper and glutamate in cell culture for production of polypeptides
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
PL2170390T3 (pl) * 2007-06-14 2019-05-31 Biogen Ma Inc Preparaty przeciwciała natalizumab
US8420081B2 (en) 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
CN101969929B (zh) * 2008-01-15 2014-07-30 Abbvie德国有限责任两合公司 粉末状蛋白质组合物及其制备方法
US20110129468A1 (en) 2008-02-29 2011-06-02 Biogen Idec Ma Inc. Purified immunoglobulin fusion proteins and methods of their purification
WO2011015926A1 (en) 2009-08-03 2011-02-10 Avesthagen Limited A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
SG10201901417UA (en) 2009-08-11 2019-03-28 Genentech Inc Production of proteins in glutamine-free cell culture media
WO2011049798A1 (en) 2009-10-20 2011-04-28 Merck Sharp & Dohme Corp. Use of mixed mode chromatography for the capture and purification of basic antibody products
WO2011079308A2 (en) 2009-12-23 2011-06-30 Emergent Product Development Seattle, Llc Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
SG185038A1 (en) 2010-04-26 2012-11-29 Novartis Ag Improved cell culture medium
WO2011141926A2 (en) * 2010-05-10 2011-11-17 Intas Biopharmaceuticals Limited Liquid formulation of polypeptides containing an fc domain of an immunoglobulin
US20130209465A1 (en) * 2010-07-30 2013-08-15 Arecor Ltd. Stabilized Aqueous Antibody Compositions
WO2012023085A1 (en) 2010-08-20 2012-02-23 Wyeth Llc Cell culture of growth factor-free adapted cells
KR20130101034A (ko) 2010-08-31 2013-09-12 프리슬랜드 브랜즈 비브이 진핵 세포를 위한 배양 배지
CA2813747A1 (en) 2010-10-11 2012-04-19 Chen Wang Processes for purification of proteins
AU2012244764B2 (en) * 2011-04-20 2016-10-13 Sandoz Ag Stable pharmaceutical liquid formulations of the fusion protein TNFR:Fc
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
KR20140054002A (ko) 2011-06-29 2014-05-08 인사이트 비젼 인코포레이티드 재발성 눈꺼풀판샘 장애를 치료하는 방법 및 이로 인해 재발 빈도를 감소시키는 방법
KR102558247B1 (ko) 2011-07-01 2023-07-24 암젠 인크 포유동물 세포 배양
EA026226B1 (ru) * 2011-07-01 2017-03-31 Байоджен Айдек Ма Инк. Не содержащие аргинина композиции слитого fc-полипептида и способы их применения
US9781540B2 (en) * 2011-07-07 2017-10-03 Qualcomm Incorporated Application relevance determination based on social context
JP6280499B2 (ja) 2011-07-08 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｆｃ融合タンパク質の精製方法
EP2753634B1 (en) 2011-08-17 2017-11-01 Ares Trading S.A. Method for preparing active form of tnfr-fc fusion protein
SG11201401562RA (en) * 2011-10-18 2014-09-26 Coherus Biosciences Inc Etanercept formulations stabilized with sodium chloride
ES2657377T3 (es) 2012-09-11 2018-03-05 Coherus Biosciences, Inc. Etanercept plegado correctamente con alta pureza y excelente rendimiento

Also Published As

Publication number Publication date
EA025267B1 (ru) 2016-12-30
US20190314500A1 (en) 2019-10-17
AU2012326084B2 (en) 2016-12-15
MX2014004726A (es) 2015-05-15
CA2851651A1 (en) 2013-04-25
KR20200008021A (ko) 2020-01-22
US10980885B2 (en) 2021-04-20
US11135267B2 (en) 2021-10-05
HK1200719A1 (en) 2015-08-14
IN2014CN02591A (es) 2015-06-26
BR112014009131A8 (pt) 2017-06-20
BR112014009131A2 (pt) 2017-06-13
JP6113176B2 (ja) 2017-04-12
JP6110393B2 (ja) 2017-04-05
JP2014530256A (ja) 2014-11-17
HK1200722A1 (en) 2015-08-14
EP2768531A4 (en) 2015-03-11
DK2768525T3 (da) 2019-07-22
EA201490815A1 (ru) 2014-09-30
IL231829A0 (en) 2014-05-28
EP2768525A1 (en) 2014-08-27
US20200405865A1 (en) 2020-12-31
WO2013059408A1 (en) 2013-04-25
TWI619504B (zh) 2018-04-01
IN2014CN02592A (es) 2015-09-04
HK1200851A1 (en) 2015-08-14
CN104010654B (zh) 2017-10-27
US20130101584A1 (en) 2013-04-25
SG11201401567YA (en) 2014-07-30
HK1200721A1 (en) 2015-08-14
HK1200720A1 (en) 2015-08-14
CN104011073A (zh) 2014-08-27
EP2768535A4 (en) 2015-03-11
BR112014009146A2 (pt) 2017-06-13
KR102163150B1 (ko) 2020-10-08
US9770510B2 (en) 2017-09-26
EA201490803A1 (ru) 2014-09-30
US10213508B2 (en) 2019-02-26
TW201325609A (zh) 2013-07-01
HK1200718A1 (en) 2015-08-14
HUE045624T2 (hu) 2020-01-28
WO2013059406A1 (en) 2013-04-25
EA201490801A1 (ru) 2014-09-30
EA027325B1 (ru) 2017-07-31
US20190290768A1 (en) 2019-09-26
EA028520B1 (ru) 2017-11-30
TW201325608A (zh) 2013-07-01
EA201490817A1 (ru) 2014-09-30
TW201325611A (zh) 2013-07-01
CN104010654A (zh) 2014-08-27
TW201325610A (zh) 2013-07-01
BR112014009031A2 (pt) 2017-05-09
EP2768531A1 (en) 2014-08-27
AU2012326171A1 (en) 2014-04-24
JP6104922B2 (ja) 2017-03-29
US20190328875A1 (en) 2019-10-31
JP6220789B2 (ja) 2017-10-25
JP6220788B2 (ja) 2017-10-25
JP2014530862A (ja) 2014-11-20
CA2851639C (en) 2020-12-29
AR088381A1 (es) 2014-05-28
EP2768533A1 (en) 2014-08-27
KR20140091705A (ko) 2014-07-22
EA026410B1 (ru) 2017-04-28
KR20140091707A (ko) 2014-07-22
EA025663B1 (ru) 2017-01-30
AU2012326170B2 (en) 2016-12-22
CN104011073B (zh) 2017-08-25
IL231825A0 (en) 2014-05-28
US20160199489A1 (en) 2016-07-14
CA2851646A1 (en) 2013-04-25
CN104010657A (zh) 2014-08-27
EP2768535A1 (en) 2014-08-27
AU2012326082B2 (en) 2016-12-15
IN2014CN02527A (es) 2015-06-26
EP2768532A1 (en) 2014-08-27
US20190290766A1 (en) 2019-09-26
EA201490804A1 (ru) 2014-09-30
JP2014530255A (ja) 2014-11-17
MX2014004725A (es) 2015-02-05
SG11201401519RA (en) 2014-07-30
HRP20191215T1 (hr) 2019-10-04
US20190216930A1 (en) 2019-07-18
CY1121843T1 (el) 2020-07-31
BR112014009146A8 (pt) 2017-06-20
KR20140079491A (ko) 2014-06-26
US9943601B2 (en) 2018-04-17
PT2768525T (pt) 2019-07-17
WO2013059412A1 (en) 2013-04-25
CN103998061A (zh) 2014-08-20
US20130101640A1 (en) 2013-04-25
EP2768532A4 (en) 2015-03-11
ES2734070T3 (es) 2019-12-04
CN103998060B (zh) 2016-12-21
KR20140083037A (ko) 2014-07-03
KR20140091706A (ko) 2014-07-22
US9801942B2 (en) 2017-10-31
EP2768525B1 (en) 2019-06-19
BR112014009022A2 (pt) 2017-05-02
AU2012326082A1 (en) 2014-04-24
AR088380A1 (es) 2014-05-28
AU2012326084A1 (en) 2014-04-17
SG11201401563SA (en) 2014-09-26
US20190290765A1 (en) 2019-09-26
EP2768854A4 (en) 2015-03-11
US20180028668A1 (en) 2018-02-01
WO2013059410A1 (en) 2013-04-25
US20180193463A1 (en) 2018-07-12
AU2012326171B2 (en) 2017-03-09
US10772963B2 (en) 2020-09-15
PL2768525T3 (pl) 2019-10-31
CA2851635A1 (en) 2013-04-25
KR20140097184A (ko) 2014-08-06
JP6199298B2 (ja) 2017-09-20
TW201325607A (zh) 2013-07-01
IL231826A0 (en) 2014-05-28
US20190298837A1 (en) 2019-10-03
MX2014004732A (es) 2015-05-15
CN103998060A (zh) 2014-08-20
IL231827A0 (en) 2014-05-28
MX2014004734A (es) 2015-05-15
EA201490802A1 (ru) 2014-08-29
US20190314499A1 (en) 2019-10-17
BR112014009073A2 (pt) 2017-05-09
MX2014004733A (es) 2015-05-15
JP2014530254A (ja) 2014-11-17
AU2012326170A1 (en) 2014-04-24
AR088383A1 (es) 2014-05-28
AU2012326168B2 (en) 2016-12-15
US20160317667A1 (en) 2016-11-03
CA2851642A1 (en) 2013-04-25
MX367054B (es) 2019-08-02
US11129876B2 (en) 2021-09-28
SI2768525T1 (sl) 2019-10-30
US20130108633A1 (en) 2013-05-02
BR112014009087A2 (pt) 2017-04-18
JP2014530863A (ja) 2014-11-20
US20190290767A1 (en) 2019-09-26
MX2019009176A (es) 2019-10-07
WO2013059407A1 (en) 2013-04-25
JP2014530864A (ja) 2014-11-20
EP2768525A4 (en) 2015-07-15
KR102068462B1 (ko) 2020-01-22
US10293049B2 (en) 2019-05-21
US9393305B2 (en) 2016-07-19
TWI644681B (zh) 2018-12-21
US9302002B2 (en) 2016-04-05
LT2768525T (lt) 2019-09-25
AU2012326080A1 (en) 2014-04-24
US20190184017A1 (en) 2019-06-20
CN104010658A (zh) 2014-08-27
AR088460A1 (es) 2014-06-11
US20180125982A1 (en) 2018-05-10
MX2014004728A (es) 2015-05-15
US10987405B2 (en) 2021-04-27
AU2012326080B2 (en) 2017-02-16
TWI595883B (zh) 2017-08-21
WO2013059405A1 (en) 2013-04-25
RS59179B1 (sr) 2019-10-31
EP2768533A4 (en) 2015-03-11
IL231824A0 (en) 2014-05-28
IL231828A0 (en) 2014-05-28
US20190314498A1 (en) 2019-10-17
TW201325606A (zh) 2013-07-01
US10888619B2 (en) 2021-01-12
US10980884B2 (en) 2021-04-20
SG11201401562RA (en) 2014-09-26
US20130108632A1 (en) 2013-05-02
SG11201401517VA (en) 2014-09-26
CA2851639A1 (en) 2013-04-25
AR088382A1 (es) 2014-05-28
CA2851628A1 (en) 2013-04-25
SG11201401576WA (en) 2014-10-30
US10376588B2 (en) 2019-08-13
AU2012326168A1 (en) 2014-04-24
EP2768854A1 (en) 2014-08-27

Similar Documents

Publication Publication Date Title
AR088379A1 (es) Formulaciones de etanercept estabilizadas con iones metalicos
ECSP15013227A (es) Formulaciones acuosas estables de adalimumab
CU24397B1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b
ZA201506916B (en) Microstructure array for delivery of active agents
DOP2016000085A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
BR112013025006A2 (pt) composições e métodos para inibição de expressão do gene tmprss6
UY35683A (es) Polimorfo de inhibidores de tirosina quinasa de bazo (syk)
BR112013028281A2 (pt) compostos e composições para inibição de nampt
TN2015000519A1 (en) Small molecule inhibitors of fibrosis
MY163083A (en) Solid forms of a pharmaceutically active substance
PH12016500720A1 (en) Stable formulation of insulin glulisine
CL2013003513A1 (es) Composicion farmaceutica que comprende un compuesto derivado de amida de formula definida o una sal del mismo y un lubricante de sal no metalica; metodo para su preparacion, util para inhibir el crecimiento de celulas con cancer.
AR093645A1 (es) Una formulacion estabilizada de pemetrexed
BR112013025866A2 (pt) formulações com viscosidade reduzida
CO7061076A2 (es) Composición farmacéutica que contiene un derivado de dihidroquinazolina antiviralmente activo
BR112013029784A2 (pt) bomba
GT201400003A (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
MX347373B (es) Soluciones anti-inflamatorias estables para inyección.
HK1217495A1 (zh) 治療活性的作為 β-羥基類固醇脫氫酶抑制劑的 -氮取代雌三烯噻唑衍生物
BR112013027222A2 (pt) composição de liberação prolongada que contém peptídeos como ingrediente ativo
BR112013029778A2 (pt) composição farmacêutica que compreende fexofenadina
BR112015009839A2 (pt) composição farmacêutica de tapentadol para administração parenteral
CR20160226A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
CR20160223A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
BR112013027390A2 (pt) formulação farmacêutica

Legal Events

Date Code Title Description
FB Suspension of granting procedure